Motif Bio PLC Webcast on Combating antibiotic resistance

TIDMMTFB

Motif Bio PLC

22 February 2016

February 22, 2016

Motif Bio plc

("Motif" or the "Company")

Motif Bio to participate in Webcast on Combating antibiotic resistance

Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Motif Bio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am ET on March 9.

> Webcast registration link

The webcast will explore some of the technologies and companies tackling the emerging antibiotic resistance crisis. Participants will learn about established approaches to combat antibiotic resistance - including antibiotic-resistance breakers, macrocycles and other antibiotic classes for infections caused by key pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.

The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this vital topic.

Dr. David Huang is an infectious diseases specialist with over 15 years of clinical, academic, industry, and research experience in medicine and in infectious diseases. He is passionate about developing new antibacterials and antivirals especially for diseases caused by multidrug resistant organisms. Other webcast participants include:

   --     Dr. Marc Lemonnier, Co-founder and CEO of Antabio 
   --     Dr. Prabhavathi Fernandes, Founder, President and CEO of Cempra Inc. 
   --     Professor Anthony R.M. Coates, Chief Scientific Officer of Helperby Therapeutics 
   --     Dr. Glenn Dale, Head of Early Development, Antimicrobials of Polyphor

-- Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

About the Webcast

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

About Motif Bio

More information is available at http://www.motifbio.com/.

For further information please contact

Enquiries

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  David Huang (Chief Medical Officer) 
  www.motifbio.com 
 Zeus Capital Limited 
  (NOMINATED ADVISER and BROKER) 
  Phil Walker/Dan Bate                   +44 (0) 20 
  Dominic Wilson                          3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell        +44 (0) 20 
  John Howes/ Mark Treharne (Broking)     7382 1100 
 
                                           +49 (0) 89 
   MC Services AG (TRADE PR)               210 2280 
   Raimund Gabriel                         +44 (0) 207 
   Shaun Brown                             148 5998 
 Plumtree Capital Limited (FINANCIAL 
  ADVISOR)                               +44 (0) 207 
  Stephen Austin                          183 2493 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Charles Goodwin                        +44 (0) 7747 
  Dominic Barretto                        788 221

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

###

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEKLFFQLFXBBE

(END) Dow Jones Newswires

February 22, 2016 02:01 ET (07:01 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024